| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-105,385 | -52,248 | -32,480 | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
3,775 | 1,019 | 680 | ||||
Stock-based compensation | ||||||
16,281 | 6,925 | 5,354 | ||||
Accretion of discount on marketable securities | ||||||
4,701 | 2,745 | - | ||||
Amortization of right-of-use assets | ||||||
1,799 | - | - | ||||
Impairment loss on right-of-use asset | ||||||
1,158 | - | - | ||||
Loss from disposal of property and equipment, net | ||||||
-39 | -151 | - | ||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
1,596 | 2,245 | 170 | ||||
Other assets | ||||||
42 | -106 | - | ||||
Accounts payable | ||||||
152 | -809 | -41 | ||||
Accrued liabilities and accrued clinical supply costs | ||||||
9,210 | 4,743 | 6,716 | ||||
Deferred revenue | ||||||
-21,219 | 172,492 | 2,128 | ||||
Deferred rent | ||||||
-44 | -7 | 28 | ||||
Lease liabilities | ||||||
868 | - | - | ||||
Other long-term liabilities | ||||||
397 | 82 | 14 | ||||
Net cash used in operating activities | ||||||
-99,308 | 127,464 | -17,771 | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | ||||||
15,265 | 1,884 | 801 | ||||
Purchase of marketable securities | ||||||
529,609 | 472,235 | - | ||||
Maturities of marketable securities | ||||||
496,000 | 250,000 | - | ||||
Net cash used in investing activities | ||||||
-48,874 | -224,119 | -801 | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock upon initial public offering, net of issuance costs | ||||||
-170,128 | 1,904 | - | ||||
Payment of deferred offering costs | ||||||
-92 | - | - | ||||
Proceeds from issuance of convertible preferred stock, net of issuance costs | ||||||
- | 133,050 | -15 | ||||
Proceeds from the exercise of options to purchase common stock | ||||||
1,519 | - | - | ||||
Proceeds from issuance of stock from employee stock purchase plan | ||||||
798 | - | - | ||||
Net cash provided by financing activities | ||||||
172,353 | 131,146 | -15 | ||||
Net increase in cash, cash equivalents, and restricted cash | ||||||
24,171 | 34,491 | -18,587 | ||||
Non-cash investing and financing activities: | ||||||
Property and equipment purchases included in accounts payable and accrued liabilities | ||||||
3,471 | 293 | 353 | ||||
Issuance costs for convertible preferred stock included in accounts payable | ||||||
- | - | 53 | ||||
Deferred offering costs in accounts payable and accrued liabilities | ||||||
465 | 792 | - | ||||
Tenant improvements paid by landlord | ||||||
8,286 | 7,449 | - | ||||